DRG Market Assessment reports
Access comprehensive market intelligence covering Disease Landscape & Forecast, Epidemiology Intelligence, Biosimilars Intelligence, China In-depth and more.
Gastroesophageal Cancer – Current Treatment – Current Treatment: Physician Insights – Gastroesophageal Cancer (US)
The gastroesophageal cancer therapy market is gaining a lot of traction. In the HER2-positive segment, trastuzumab-based regimens, with or without Keytruda, continue to dominate. Meanwhile, the…
Hospital-Treated Gram-Negative Infections – Current Treatment – Current Treatment: Physician Insights – Hospital-Treated Gram-Negative Infections (US)
Most inpatients with hospital-treated gram-negative infections (GNIs) are successfully treated empirically with generic antibiotics. These agents continue to dominate the hospital-treated GNI…
Gastroesophageal Cancer – Current Treatment – Treatment Sequencing – Gastroesophageal Cancer (US)
Key benefits and usesPinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into physicians’ treatment sequences and understand who to position against…
Chronic Obstructive Pulmonary Disease – Access & Reimbursement – Access & Reimbursement – Chronic Obstructive Pulmonary Disease (US)
The dynamics within the LAMA, LABA/LAMA, LABA/ICS FDC, and LABA/LAMA/ICS FDC drug classes will continue to shape the U.S. COPD market, as will the market entry of Verona’s nebulized PDE-3/PDE-4…
Squamous Cell Carcinoma of the Head and Neck – Unmet Need – Unmet Need – Recurrent or Metastatic Non-Nasopharyngeal Squamous Cell Carcinoma of Head and Neck (US/EU)
Recurrent or metastatic non-nasopharyngeal squamous cell carcinoma of the head and neck is an aggressive malignancy associated with a high recurrence rate. The approval of immune checkpoint…
